Working… Menu

Lymphocyte and Cytokine Disturbances in Polymyalgia Rheumatica (TENOR-IMMUNO)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02888496
Recruitment Status : Completed
First Posted : September 5, 2016
Last Update Posted : September 5, 2016
Information provided by (Responsible Party):
University Hospital, Brest

Brief Summary:
Pathophysiology of polymyalgia rheumatica (PMR) is ill defined. This study aims at characterizing immunological abnormalities in PMR patients, and to assess the effects of tocilizumab therapy on this abnormalities.

Condition or disease Intervention/treatment
Polymyalgia Rheumatica Drug: tocilizumab

Detailed Description:
Comparison of PMR patients and matched control subjects.

Layout table for study information
Study Type : Observational
Actual Enrollment : 40 participants
Observational Model: Case Control
Time Perspective: Prospective
Official Title: Caractérisation Des Anomalies Immunologiques au Cours de la Pseudopolyarthrite rhizomélique et Effets du Traitement Par Tocilizumab
Study Start Date : January 2015
Actual Primary Completion Date : June 2015
Actual Study Completion Date : June 2015

Group/Cohort Intervention/treatment
PMR patients
Patients included in the clinical trial TENOR (prospective open-labeled study of tocilizumab in treatment-naïve PMR patients)
Drug: tocilizumab
3 monthly IV infusions in PMR patients
Other Name: anti-IL-6 receptor monoclonal antibody

Healthy controls
Matched to PMR patients for sex and age, exclusion of any autoimmune, inflammatory, neoplastic and chronic infectious disease

Primary Outcome Measures :
  1. Proportion of blood lymphocyte populations (T cells, B cells, NK cells) [ Time Frame: 6 months ]
    Lymphocyte subset analysis by flow cytometry

Secondary Outcome Measures :
  1. Serum cytokine concentration measurement [ Time Frame: 6 months ]
    Cytokine level measurements using an array and ELISAs

Biospecimen Retention:   Samples Without DNA

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
PMR patients included in the TENOR study (NCT01713842).

Inclusion Criteria:

  • PMR patient included in the TENOR study with samples available

Exclusion Criteria:

  • Patient not included in the TENOR study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02888496

Layout table for location information
CHRU de Brest
Brest, France, 29609
Sponsors and Collaborators
University Hospital, Brest
Layout table for investigator information
Study Director: Divi Cornec CHRU de Brest

Layout table for additonal information
Responsible Party: University Hospital, Brest Identifier: NCT02888496     History of Changes
Other Study ID Numbers: TENOR-IMMUNO
First Posted: September 5, 2016    Key Record Dates
Last Update Posted: September 5, 2016
Last Verified: August 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Polymyalgia Rheumatica
Giant Cell Arteritis
Muscular Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Vasculitis, Central Nervous System
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Skin Diseases, Vascular
Skin Diseases
Autoimmune Diseases
Immune System Diseases